Gary A. Shangold

GARY A. SHANGOLD is the President and Chief Executive Officer of NovaDel
Pharma Inc., a specialty pharmaceutical company which has a proprietary
technology for delivering drugs via lingual spray for rapid absorption
from the oral mucosal membranes. Dr. Shangold received a BA cum laude
from the University of Pennsylvania in his major field of Social
Behavior. He graduated from Columbia University’s College of Physicians
and Surgeons with a Doctor of Medicine degree. He then completed his
residency training in Obstetrics and Gynecology at the University of
Miami (Jackson Memorial Hospital) and a fellowship in Reproductive
Endocrinology at the University of Southern California (Los Angeles
County Medical Center). He is board-certified in Obstetrics and
Gynecology and subspecialty-boarded in Reproductive Endocrinology.
Following the completion of his training, Dr. Shangold held the
positions of Assistant Professor and then Associate Professor of
Obstetrics and Gynecology at the University of Chicago Pritzker School
of Medicine. In 1991, he moved from academia into the pharmaceutical
industry as the Medical Director for Obstetrics, Gynecology and
Infertility at Serono Laboratories. He subsequently moved to Johnson &
Johnson as Senior Director of Gynecologic and Reproductive Clinical
Research, and then becoming the Contraception Global Product Team
Leader, at the R.W. Johnson Pharmaceutical Research Institute. Later he
was promoted to the position of Vice President and Regulatory Head of
Drug Development at Johnson & Johnson Pharmaceutical Research &
Development, LLC. From 1991 through 2003, Dr. Shangold was affiliated
with the Harvard University School of Medicine as Associate Clinical
Professor of Obstetrics, Gynecology and Reproductive Biology and as a
Clinical Associate in the Department of Obstetrics and Gynecology at
Massachusetts General Hospital.